Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability and
pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy
type 3